On September 28, 2021 panCELLa Inc. and its subsidiary, Implant Therapeutics, reported their partnership with Angios Biotech to evaluate the efficacy of our technologies as incorporated into allogeneic vascular transplants derived from IPSC (Press release, panCELLa, SEP 28, 2021, View Source [SID1234590462]). Angios is developing true blood vessels which are fundamental to engineering tissue and complex cell products for therapy. panCELLa believes our FailSafeTM and Stealth CellsTM technology will guarantee long term engraftment of their cells and ensure an unprecedented level of safety.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Our companies are committed to providing the highest quality of cells for therapy. Mahendra Rao, CEO of panCELLa and founder of Implant, notes: "the collaboration of Angios with panCELLa and Implant brings together experts, across two continents, on pluripotent stem cells, gene editing and cell differentiation to treat diseases that require vascular reconstitution. The Stealth CellsTM protect the therapeutic cell treatment from the patient’s immune system offering long-term allo-tolerance without the need for immune suppression. panCELLa’s FailSafeTM is a superior safety switch. Unlike others, it will not be lost or silenced since it is precisely linked to cell division. At any time that cells deregulate or "go rogue" they can be eliminated while still allowing the therapeutic non-dividing cells to continue to do their work.
There is considerable potential for vascular cell therapies as many long-term injuries are currently not adequately served with existing treatment options. Safety and transplant tolerance are two pillars of successful cell therapy, which are both facilitated by the collaboration with panCELLa. "The partnership of panCELLa with Angios is truly accelerating our development of safe allogenic vascular transplants for the treatment of severe vascular diseases." says Gregor Wick, CEO of Angios.